Versartis Secures $25,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0cb8aacf-0c5e-42ff-b915-a47e6641e77b&Preview=1 -
Date
1/15/2013 -
Company Name
Versartis -
Mailing Address
500 Ellis Street Mountain View, CA 94043 -
Company Description
Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix. -
Website
http://www.versartis.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The primary use of the proceeds will be to fund clinical trials of its leadproduct, VRS-317, for growth hormone deficiency (GHD) in pediatric patients. VRS-317 is a proprietary once monthly form of recombinant humangrowth hormone (rhGH). -
M&A Terms
-
Venture Investor
Aisling Capital -
Venture Investor
Index Ventures -
Venture Investor
New Leaf Venture Partners -
Venture Investor
Advent Venture Partners
